{"title":"The emerging role of graphene in spinal cord regeneration.","authors":"Paula A A P Marques","doi":"10.1080/17435889.2025.2475732","DOIUrl":"10.1080/17435889.2025.2475732","url":null,"abstract":"","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1081-1084"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marwa Elhariry, Alina Oknianska, Jorge Garcia-Lara, Robert Shorten, Boris Oberheitmann, Tapas Sen
{"title":"Nanomaterials for bacterial enrichment and detection in healthcare.","authors":"Marwa Elhariry, Alina Oknianska, Jorge Garcia-Lara, Robert Shorten, Boris Oberheitmann, Tapas Sen","doi":"10.1080/17435889.2025.2488724","DOIUrl":"10.1080/17435889.2025.2488724","url":null,"abstract":"<p><p>Bacterial infections in the blood (sepsis) have been recognized as a leading cause of mortality in the clinical field due to limitations in the detection of bacteria at low concentration and their resistance to antibiotics by excessive misuse. Some of the common symptoms are fever, chills, rapid heartbeat, difficulty breathing, confusion, and changes in mental status with occasionally pale, clammy, and mottled skin. Early diagnosis and identification are the keys to a successful treatment for sepsis patients. Researchers have developed nanoparticles to enrich bacterial populations followed by detection and applied them to conventional methods such as phenotypic and molecular diagnostics to enhance different detectors' responses toward pathogens. This short review systematically overviews steps that are followed in clinical labs for bacterial detection, identification, and their drawbacks. In this context, we discuss the role that nanoparticles can play in overcoming the limits of traditional microbiology methods in terms of turnaround times (TATs) and accuracy. We believe that this short review will provide up-to-date information about the applications of nanoparticles in the enrichment, separation, and identification of bacterial infection in the clinical field and, therefore, a way of rapid treatment.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"985-1000"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rana Elfatairi, Jessica Ou, Vincent Lebreton, Mariam Mahdjoub, Norraseth Kaeokhamloed, Jérôme Bejaud, Grégory Hilairet, Florence Gattacceca, Emilie Roger, Samuel Legeay
{"title":"Specific quantification of intact lipid nanocapsules in rats using FRET: biodistribution and PBPK model development.","authors":"Rana Elfatairi, Jessica Ou, Vincent Lebreton, Mariam Mahdjoub, Norraseth Kaeokhamloed, Jérôme Bejaud, Grégory Hilairet, Florence Gattacceca, Emilie Roger, Samuel Legeay","doi":"10.1080/17435889.2025.2492537","DOIUrl":"10.1080/17435889.2025.2492537","url":null,"abstract":"<p><strong>Aims: </strong>One major challenge is to quantify intact nanoparticles specifically to understand the pharmacokinetics (PK) of nanomedicines. Lipid nanocapsules (LNC) carrying Förster resonance energy transfer (FRET) trackers have been previously developed, and a quantification method has been applied in blood samples.</p><p><strong>Materials & method: </strong>A quantification method in liver, spleen, and lungs was developed, and the biodistribution of intact FRET-LNC of 50 nm (FRET-LNC-50) in rats after intravenous injection was performed.</p><p><strong>Results: </strong>FRET-LNC-50 were extracted from organs using a newly developed extraction method, allowing their integrity preservation and quantification. This method allowed the assessment of the biodistribution study of intact LNC. A non-compartmental PK analysis was performed to calculate PK parameters. The most exposed organ was the liver, with a longer half-life than blood and other organs. The availability of specific biodistribution data allowed the development of the first physiologically based PK (PBPK) model, which represents an ideal platform to further aggregate biodistribution data from various nanoparticle types and to bring insight into PK mechanisms and structure-properties relationships of nanoparticles.</p><p><strong>Conclusion: </strong>This study presents the first biodistribution analysis of intact LNC using a validated quantification method, enabling the development of a PBPK model that improves the understanding of nanoparticle PK mechanisms.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":"20 10","pages":"1101-1112"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068743/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mohammad Reza Fattahi, Mostafa Baghlani, Scott E Eggener, Mansoureh Dehghani, Mohammad-Mehdi Khani, Abdolmohammad Kajbafzadeh
{"title":"MXene and prostate cancer: is there promising news?","authors":"Mohammad Reza Fattahi, Mostafa Baghlani, Scott E Eggener, Mansoureh Dehghani, Mohammad-Mehdi Khani, Abdolmohammad Kajbafzadeh","doi":"10.1080/17435889.2025.2487412","DOIUrl":"10.1080/17435889.2025.2487412","url":null,"abstract":"<p><p>Prostate cancer is the most prevalent cancer among men worldwide, and there have been many advances in its diagnosis and treatment. However, critical obstacles remain, including overdiagnosis, high rates of negative biopsies, management of side effects, and the timely detection of relapse. Despite these improvements, surgery and radiotherapy are still associated with a significant risk of short- or long-term side effects. MXenes are a novel class of two-dimensional nanomaterials manufactured through electrochemical procedures that accept a wide-termination of hydrophilic molecules as surface modifications. The importance of MXene has increased owing to many aspects, such as its high-gain synthesis potential, chemical flexibility, and high biocompatibility. Hence, MXene is a convenient nanomaterial that can be modified and synthesized in different models, suggesting its ability to improve screening, diagnosis, and theranostic applications, such as thermal therapy. These features have been used to detect potential urothelial tumor markers as well as the direction and accumulation of cancer medications in the target tissue.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":"20 9","pages":"1001-1014"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144037957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Advances in cancer nanovaccines: a focus on colorectal cancer.","authors":"Yalda Ghazizadeh, Hossein Salehi Shadkami, Fatemeh Madani, Sedigheh Niknam, Mahdi Adabi","doi":"10.1080/17435889.2025.2486930","DOIUrl":"10.1080/17435889.2025.2486930","url":null,"abstract":"<p><p>Nanotechnology has revolutionized cancer treatment by providing innovative solutions through nanocancer therapies, nanovaccines, and nanoparticles. This review focuses on the application of these technologies in colorectal cancer (CRC), highlighting their progression from preclinical studies to clinical trials. Nanoparticles, including liposomes, silica, gold, and lipid nanoparticles, possess unique properties that enhance drug delivery, improve therapeutic efficacy, and minimize systemic toxicity. Additionally, nanovaccines are being developed to elicit robust immune responses against CRC cells. This paper offers a comprehensive overview of the current state of nanotechnology-based treatments for CRC, emphasizing key preclinical studies and clinical trials that demonstrate their potential. Furthermore, the review discusses the challenges faced in this field. It outlines future directions for research, underscoring the need for ongoing efforts to translate these promising technologies into practical clinical applications.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1029-1041"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"How can membrane lipid constituency be manipulated to produce liposomes with desired functions?","authors":"T Issler, S Lisowski, K Farzi, E J Prenner","doi":"10.1080/17435889.2025.2469485","DOIUrl":"10.1080/17435889.2025.2469485","url":null,"abstract":"","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"921-923"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143484995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Realizing the potential of nanomedicines to treat breast cancer liver metastasis.","authors":"Biana Godin, Hermann B Frieboes","doi":"10.1080/17435889.2025.2469491","DOIUrl":"10.1080/17435889.2025.2469491","url":null,"abstract":"","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1073-1076"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Results of phase Ib/II trial of PEP503 (NBTXR3, radioenhancer) with chemoradiotherapy in patients with rectal cancer.","authors":"Ching-Wen Huang, Huang-Ming Hu, Wen-Hung Hsu, Chiao-Yun Chen, Ming-Yii Huang, Chou-Pin Chen, Po-Li Wei, Bor-Nian Shen, Tsung-Kun Chang, Jaw-Yuan Wang","doi":"10.1080/17435889.2025.2487411","DOIUrl":"10.1080/17435889.2025.2487411","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the efficacy, recommended phase II dose (RP2D), dose-limiting toxicity (DLT), and safety profiles of PEP503 (NBTXR3) in combination with concurrent chemoradiotherapy (CCRT) in patients with locally advanced or unresectable rectal adenocarcinoma.</p><p><strong>Methods: </strong>A single administration of intratumor injection of PEP503 (NBTXR3) (multiple punctures) was applied, followed by radiotherapy in combination with capecitabine or 5-fluorouacil (5-FU). Surgery was performed 8 to 12 weeks after completion of CCRT.</p><p><strong>Results: </strong>Thirty-two patients were enrolled (one dropped out before CCRT), comprising 20 in phase Ib and 12 in phase II. The disease control rate was 100% (<i>n</i> = 31). One (3.2%) and 19 (61.3%) patients achieved clinical complete response and partial response, respectively. Twenty-five patients underwent surgery, of whom 24 (96%) had R0 resection and 5 (20%) had pathological complete response. Most of the adverse events were grade 1/2 events.</p><p><strong>Conclusion: </strong>Intratumor injection of PEP503 (NBTXR3) in patients with locally advanced or unresectable rectal adenocarcinoma is safe and effective. Addition of PEP503 (NBTXR3) to fluoropyrimidine-based neoadjuvant CCRT does not engender increased toxicity. The strong safety profile and encouraging efficacy of PEP503 (NBTXR3) in combination with neoadjuvant CCRT in locally advanced or unresectable rectal cancer warrant further examination in clinical studies.</p><p><strong>Clinical trial registration: </strong>This study was registered on ClinicalTrials.gov Identifier: NCT02465593.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":"20 9","pages":"929-941"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Karen Alvarez, Cristian A Anacona, Esneyder Ruiz Agudelo, Paula Losada, Víctor H Orozco, Luis Fernando Giraldo, Gloria Vásquez, Daniel Rodriguez, Juan Camilo Díaz, Ricardo Pineda, Mauricio Rojas
{"title":"Wheat germ agglutinin-nanoparticles encapsulating itacitinib target and suppress pro-inflammatory slan+ monocytes.","authors":"Karen Alvarez, Cristian A Anacona, Esneyder Ruiz Agudelo, Paula Losada, Víctor H Orozco, Luis Fernando Giraldo, Gloria Vásquez, Daniel Rodriguez, Juan Camilo Díaz, Ricardo Pineda, Mauricio Rojas","doi":"10.1080/17435889.2025.2494500","DOIUrl":"10.1080/17435889.2025.2494500","url":null,"abstract":"<p><strong>Background: </strong>6-sulfoLacNAc (slan)+ monocytes, a non-classical monocyte subset, play a pro-inflammatory role in autoimmune diseases like systemic lupus erythematosus (SLE). This study evaluates the therapeutic potential of itacitinib (ITA) encapsulated in wheat germ agglutinin-functionalized nanoparticles (WGA/F127/PNPs) to target and inhibit the JAK-STAT pathway in slan+ monocytes.</p><p><strong>Methods: </strong>We prepared ITA-loaded WGA/F127/PNPs and analyzed their binding and internalization in various leukocyte subsets using flow cytometry, focusing on slan+ and slan- monocytes. Further, peripheral blood samples from healthy controls (<i>n</i> = 37) and SLE patients (<i>n</i> = 50) were used to assess slan+ monocyte phenotypes. Co-cultures of slan+ and slan- monocytes stimulated with LPS revealed that slan+ monocytes significantly increased HLA-DR expression.</p><p><strong>Results: </strong>Results showed that slan+ monocytes from SLE patients were reduced compared to healthy controls (<i>p</i> < 0.001) and that slan+ monocytes effectively internalized WGA/F127/PNPs, unlike slan- cells. ITA-loaded nanoparticles decreased HLA-DR, CD69, and CD86 expression, STAT1 phosphorylation, and cytokine production in IFN-γ-stimulated slan+ monocytes. Findings support WGA/F127/PNPs as a promising drug delivery system for targeting slan+ monocytes, providing new therapeutic potential for SLE.</p><p><strong>Conclusion: </strong>ITA-loaded WGA/F127/PNPs effectively target and suppress pro-inflammatory slan+ monocytes, presenting a promising, cell-specific therapeutic approach for managing systemic lupus erythematosus and related autoimmune disorders.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":"20 10","pages":"1113-1126"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Synergistic approach of PEGylated photothermal agent and immunomodulator in cancer immunotherapy.","authors":"Gong Yi Yong, Anyanee Kamkaew, Chin Siang Kue","doi":"10.1080/17435889.2025.2489342","DOIUrl":"10.1080/17435889.2025.2489342","url":null,"abstract":"<p><p>Photothermal therapy (PTT) utilizes photothermal agents (PTAs) to generate heat at the local tumor site that leads to ablation upon photoirradiation at a specific wavelength of light. Currently, most of the available PTAs have weak tumor selectivity and depositing ability, which leads to poor therapeutic outcomes. PEGylation of PTAs improves therapeutic outcomes, prolongs systemic circulation time, enhances tumor accumulation, and reduces the risk of clearance by the immune system. This paper reviews the recent developments of PEGylated PTAs in photothermal cancer therapy from 2019 to 2023, highlighting their antitumour efficacy and immune response post-therapy with immune agents, current challenges and strategies. This review aims to foster knowledge dissemination on the application of nanomedicine in photothermal cancer therapy from an immunological perspective and to encourage the clinical translation of these nanomaterials.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":"20 9","pages":"967-983"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}